Ironwood Pharmaceuticals Inc (NASDAQ: IRWD)’s stock price has dropped by -1.95 in relation to previous closing price of 0.62. Nevertheless, the company has seen a loss of -2.04% in its stock price over the last five trading days. zacks.com reported 2025-05-08 that Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Is It Worth Investing in Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Right Now?
Additionally, the 36-month beta value for IRWD is 0.23. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for IRWD is 156.14M and currently, short sellers hold a 5.42% ratio of that float. The average trading volume of IRWD on June 04, 2025 was 3.32M shares.
IRWD’s Market Performance
The stock of Ironwood Pharmaceuticals Inc (IRWD) has seen a -2.04% decrease in the past week, with a -34.58% drop in the past month, and a -59.07% fall in the past quarter. The volatility ratio for the week is 5.30%, and the volatility levels for the past 30 days are at 7.27% for IRWD. The simple moving average for the past 20 days is -6.72% for IRWD’s stock, with a -79.11% simple moving average for the past 200 days.
IRWD Trading at -32.55% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.42% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from MCCOURT Thomas A, who sale 13,353 shares at the price of $0.58 back on May 16 ’25. After this action, MCCOURT Thomas A now owns 1,147,281 shares of Ironwood Pharmaceuticals Inc, valued at $7,745 using the latest closing price.
Gaskins Tammi L, the Chief Commercial Officer of Ironwood Pharmaceuticals Inc, sale 2,563 shares at $0.58 during a trade that took place back on May 16 ’25, which means that Gaskins Tammi L is holding 242,596 shares at $1,487 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 1.0 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc stands at -0.1. The total capital return value is set at 0.2. Equity return is now at value -559.14, with -8.20 for asset returns.
Based on Ironwood Pharmaceuticals Inc (IRWD), the company’s capital structure generated 2.26 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at -1.79. The interest coverage ratio of the stock is 1.63.
Currently, EBITDA for the company is 100.24 million with net debt to EBITDA at 8.24. When we switch over and look at the enterprise to sales, we see a ratio of 1.86. The receivables turnover for the company is 7.99for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.
Conclusion
In conclusion, Ironwood Pharmaceuticals Inc (IRWD) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
